Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer.

JAMA network open - 1 Mar 2022

Graf Ryon P, Fisher Virginia, Weberpals Janick, Gjoerup Ole, Tierno Marni B, Huang Richard S P, Sayegh Nicolas, Lin Douglas I, Raskina Kira, Schrock Alexa B, Severson Eric, Haberberger James F, Ross Jeffrey S, Creeden James, Levy Mia A, Alexander Brian M, Oxnard Geoffrey R, Agarwal Neeraj

Abstract excerpt

Importance: The most useful biomarkers for clinical decision-making identify patients likely to have improved outcomes with one treatment vs another. Objective: To evaluate treatment class-specific outcomes of patients receiving immune checkpoint inhibitor (ICI) vs taxane chemotherapy by tumor mutational burden (TMB). Design, Setting, and Participants: This comparative effectiveness analysis of clinical variables...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Genomics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Mutation

Share to Prostatic Neoplasms, Castration-Resistant

Source

Open in PubMed Open full text

Identifiers

PMID: 35357449
DOI: 10.1001/jamanetworkopen.2022.5394
PMCID: PMC8972027

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer.PMID 35357449Read ↗

Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial.Semantic proximity Read ↗

Comparison of Real-World Outcomes between Patients with BRCA1/2-Positive and Homologous Recombination Repair-Negative Metastatic Castration-Sensitive Prostate CancerSemantic proximity Read ↗

Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial.Semantic proximity Read ↗

Homologous Recombination Repair Mutations, Next-generation Sequencing Testing, and Treatment Progression by Race Among Patients With Metastatic Castration-sensitive Prostate Cancer.Semantic proximity Read ↗

Comparison of circulating tumor DNA between African American and Caucasian patients with metastatic castrate-resistant prostate cancer post-abiraterone and/or enzalutamide.Semantic proximity Read ↗

The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited.Semantic proximity Read ↗

A Real-World Experience of Pembrolizumab Monotherapy in Microsatellite Instability-High and/or Tumor Mutation Burden-High Metastatic Castration-Resistant Prostate Cancer: Outcome AnalysisSemantic proximity Read ↗

Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair DefectsSemantic proximity Read ↗

Real-World Overall Survival and Treatment Patterns by PTEN Status in Metastatic Castration-Resistant Prostate CancerSemantic proximity Read ↗

Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway InhibitionSemantic proximity Read ↗

Differential Response to 177Lu-PSMA-617 in Patients with Tumor Suppressor Gene-Mutated Metastatic Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.